AUBURN, AL (WTVM) - Researchers at Auburn University have discovered a platform that allows health professionals to target diseases that antibiotics cannot reach.
AU's Veterinary Department has discovered a treatment that addresses intracellular diseases that are not normally cured by antibiotics.
"We need to have a vaccine that creates a lot of T-Cells and there's nothing like that available on the market. All vaccines usually try to raise a lot of antibodies," explains Dr. Bernhard Kaltenboeck, AU Professor of Pathobiology.
To achieve that goal, Kaltenboeck and his team tried something new.
Typically, large doses of vaccine are given because that means more antibodies are produced. Instead, they drastically lowered the dose.
"What we found essentially is it's not just half or a quarter of what you use normally, its less than one hundredth of one percent of the amount that is required to get a good T-cell immunity response," says Kaltenboeck.
Such a response can serve as a preventive measure or as a way to treat many diseases.
"Such a platform of technology that we want to use, not only for Chlamydia, but for other intracellular diseases tuberculosis, malaria, a lot of different organisms fall into this category," explains Kaltenboeck.
This vaccine would also be completely manmade by using only short, synthetic protein fragments, or peptides, from the disease target.
This would prove the Auburn platform to be not only safer, but also much less expensive.
"It has the potential to change the vaccine world basically, we just don't know yet," says Kaltenboeck.
A patent is pending and the team has begun marketing the technology to major human and animal health companies.
And while it is still in its early stages, the projected low cost of the vaccine would allow it to be distributed more widely, in developing countries.